Article Cited by others


Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer

Stein Mark N, Patel Neal, Bershadskiy Alexander, Sokoloff Alisa, Singer Eric A

Year : 2014| Volume: 16| Issue : 3 | Page no: 387-400

   This article has been cited by
1 Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay
Joseph Shaw,Mathew Leveridge,Charlotta Norling,Jakob Karén,Daniel Martinez Molina,Daniel O’Neill,James E. Dowling,Paul Davey,Suzanna Cowan,Michael Dabrowski,Martin Main,Davide Gianni
Scientific Reports. 2018; 8(1)
[Pubmed]  [Google Scholar] [DOI]
2 Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
Charles F. Polotti,Christopher J. Kim,Nadiya Chuchvara,Alyssa B. Polotti,Eric A. Singer,Sammy Elsamra
Expert Opinion on Drug Metabolism & Toxicology. 2017; 13(12): 1265
[Pubmed]  [Google Scholar] [DOI]
3 First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
Mikhail Paltsev,Vsevolod Kiselev,Vadim Drukh,Ekaterina Muyzhnek,Igor Kuznetsov,Evgeniya Andrianova,Pavel Baranovskiy
EPMA Journal. 2016; 7(1)
[Pubmed]  [Google Scholar] [DOI]
4 Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
Sameer S. Udhane,Bernhard Dick,Qingzhong Hu,Rolf W. Hartmann,Amit V. Pandey
Biochemical and Biophysical Research Communications. 2016;
[Pubmed]  [Google Scholar] [DOI]
5 Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer
D. S. Mikhaylenko,G. D. Efremov,A. V. Sivkov,D. V. Zaletaev
Molecular Biology. 2016; 50(1): 28
[Pubmed]  [Google Scholar] [DOI]
6 The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature
Ian M. Bird,David H. Abbott
The Journal of Steroid Biochemistry and Molecular Biology. 2016;
[Pubmed]  [Google Scholar] [DOI]
7 CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Anitha B. Alex,Sumanta K. Pal,Neeraj Agarwal
Therapeutic Advances in Medical Oncology. 2016; 8(4): 267
[Pubmed]  [Google Scholar] [DOI]
8 Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Archana Anantharaman,Terence W. Friedlander
Urologic Oncology: Seminars and Original Investigations. 2015;
[Pubmed]  [Google Scholar] [DOI]
9 Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Christopher Sejong Han,Rutveej Patel,Isaac Yi Kim
Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(6): 967
[Pubmed]  [Google Scholar] [DOI]
10 Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)
Richard L Schroeder,Phan Tram,Jiawang Liu,Maryam Foroozesh,Jayalakshmi Sridhar
Expert Opinion on Therapeutic Patents. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
11 The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells
Lingling Fan,Guihong Peng,Arif Hussain,Ladan Fazli,Emma Guns,Martin Gleave,Jianfei Qi
Journal of Biological Chemistry. 2015; 290(34): 20865
[Pubmed]  [Google Scholar] [DOI]
12 Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)
International Journal of Oncology. 2014; 45(4): 1337
[Pubmed]  [Google Scholar] [DOI]


Read this article